These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38626090)

  • 1. Correction: Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies.
    Armstrong LA; Lange SM; Cesare V; Matthews SP; Nirujogi RS; Cole I; Hope A; Cunningham F; Toth R; Mukherjee R; Bojkova D; Gruber F; Gray D; Wyatt PG; Cinatl J; Dikic I; Davies P; Kulathu Y
    PLoS One; 2024; 19(4):e0302418. PubMed ID: 38626090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies.
    Armstrong LA; Lange SM; Dee Cesare V; Matthews SP; Nirujogi RS; Cole I; Hope A; Cunningham F; Toth R; Mukherjee R; Bojkova D; Gruber F; Gray D; Wyatt PG; Cinatl J; Dikic I; Davies P; Kulathu Y
    PLoS One; 2021; 16(7):e0253364. PubMed ID: 34270554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Method to Monitor Activity of SARS-CoV-2 Nsp3 from Cells.
    Rainville C; Sterner DE; Suresh K
    Methods Mol Biol; 2023; 2591():269-282. PubMed ID: 36350554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species.
    Moustaqil M; Ollivier E; Chiu HP; Van Tol S; Rudolffi-Soto P; Stevens C; Bhumkar A; Hunter DJB; Freiberg AN; Jacques D; Lee B; Sierecki E; Gambin Y
    Emerg Microbes Infect; 2021 Dec; 10(1):178-195. PubMed ID: 33372854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction to "Scalable Inhibitors of the Nsp3-Nsp4 Coupling in SARS-CoV-2".
    Azizogli AR; Pai V; Coppola F; Jafari R; Dodd-O JB; Harish R; Balasubramanian B; Kashyap J; Acevedo-Jake AM; Kral P; Kumar VA
    ACS Omega; 2024 Aug; 9(34):36857. PubMed ID: 39220492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Factors associated with SARS-COV-2 positive test in Lifelines.
    Sidorenkov G; Vonk JM; Grzegorczyk M; Cortés-Ibañez FO; de Bock GH
    PLoS One; 2024; 19(4):e0302619. PubMed ID: 38640095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction: Covid-19 in outpatients-Is fever a useful indicator for SARS-CoV-2 infection?
    Schneider A; Kirsten H; Lordick F; Lordick F; Lübbert C; von Braun A
    PLoS One; 2021; 16(5):e0251623. PubMed ID: 33956896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease.
    Qiao H; Li L; Wang L; Yu H; Hu F; Zhou X; Yang H; Xu J; Meng X; Geng Y; Dai Y
    Protein Expr Purif; 2023 Jul; 207():106267. PubMed ID: 37030644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: SARS-CoV-2 transmission routes from genetic data: A Danish case study.
    PLOS ONE Staff
    PLoS One; 2021; 16(12):e0261892. PubMed ID: 34932605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction: Identifying key determinants and dynamics of SARS-CoV-2/ACE2 tight interaction.
    Ngo VA; Jha RK
    PLoS One; 2021; 16(11):e0259705. PubMed ID: 34731214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya.
    Gignoux E; Athanassiadis F; Yarrow AG; Jimale A; Mubuto N; Déglise C; Mosoti DO; Azman AS; Mwau M; Luquero F; Ciglenecki I
    PLoS One; 2024; 19(2):e0299117. PubMed ID: 38354210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: Sociodemographic characteristics and risk factors related to SARS-CoV-2 infection in Luanda, Angola.
    Sebastião CS; Neto Z; Martinez P; Jandondo D; Antonio J; Galangue M; de Carvalho M; David K; Miranda J; Afonso P; Inglês L; Carrelero RR; de Vasconcelos JN; Morais J
    PLoS One; 2021; 16(5):e0252254. PubMed ID: 34015031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: Harnessing the power of AI: Advanced deep learning models optimization for accurate SARS-CoV-2 forecasting.
    Tariq MU; Ismail SB; Babar M; Ahmad A
    PLoS One; 2023; 18(12):e0296111. PubMed ID: 38096185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: The first wave of the SARS-CoV-2 epidemic in Tuscany (Italy): A SI2R2D compartmental model with uncertainty evaluation.
    PLOS ONE Staff
    PLoS One; 2021; 16(6):e0252908. PubMed ID: 34077480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Detection of SARS-CoV-2 RNA by direct RT-qPCR on nasopharyngeal specimens without extraction of viral RNA.
    Hasan MR; Mirza F; Al-Hail H; Sundararaju S; Xaba T; Iqbal M; Alhussain H; Yassine HM; Perez-Lopez A; Tang P
    PLoS One; 2020; 15(10):e0240343. PubMed ID: 33007037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: Menstrual cycle changes: A cross-sectional study of Saudi females following SARS-CoV-2 infection.
    Abdel-Moneim YAS; Alghamdi HY; Alrashed AM; Jawhari AM; Bukhari SMM; Bukhari NMM; Abdel-Moneim AS
    PLoS One; 2024; 19(3):e0301574. PubMed ID: 38536839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Host Interactomes of the SARS-CoV-2 Nonstructural Protein 3 and Human Coronavirus Homologs.
    Almasy KM; Davies JP; Plate L
    Mol Cell Proteomics; 2021; 20():100120. PubMed ID: 34186245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative host interactomes of the SARS-CoV-2 nonstructural protein 3 and human coronavirus homologs.
    Almasy KM; Davies JP; Plate L
    bioRxiv; 2021 Mar; ():. PubMed ID: 33758849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples.
    Mullins E; McCabe R; Bird SM; Randell P; Pond MJ; Regan L; Parker E; McClure M; Donnelly CA
    PLoS One; 2024; 19(8):e0308512. PubMed ID: 39088582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders.
    Marklund E; Leach S; Axelsson H; Nyström K; Norder H; Bemark M; Angeletti D; Lundgren A; Nilsson S; Andersson LM; Yilmaz A; Lindh M; Liljeqvist JÅ; Gisslén M
    PLoS One; 2021; 16(10):e0258401. PubMed ID: 34606511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.